Pefloxacin Mesylate Dihydrate

• CAT Number: A000421
• CAS Number: 149676-40-4
• Molecular Formula: C18H28FN3O8S
• Molecular Weight: 465.49
• Purity: ≥95%
• Synonyms: 1589 RB
• Target: Bacterial
• Solubility: >11.275mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid;dihydrate
• InChI: InChI=1S/C17H20FN3O3.CH4O3S.2H2O/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21;1-5(2,3)4;;/h8-10H,3-7H2,1-2H3,(H,23,24);1H3,(H,2,3,4);2*1H2
• InChIKey: LEULAXMUNMRLPW-UHFFFAOYSA-N
• SMILES: CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O.CS(=O)(=O)O.O.O

Pefloxacin Mesylate Dihydrate（Cat No.:A000421）is a potent antibacterial agent used for the treatment of various bacterial infections. This compound belongs to the fluoroquinolone class of antibiotics and is effective against a broad spectrum of Gram-negative and Gram-positive bacteria. The mesylate salt form enhances the drug’s solubility and bioavailability. Pefloxacin Mesylate Dihydrate works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, leading to bactericidal effects. It is commonly used in the treatment of respiratory and urinary tract infections.

Reference

1: Li A, Song Z. Study of silver nanoparticles sensitized fluorescence and second-order scattering of terbium(III)-pefloxacin mesylate complex and determination of pefloxacin mesylate. ScientificWorldJournal. 2014;2014:742935. doi: 10.1155/2014/742935. Epub 2014 May 6. PubMed PMID: 24892083; PubMed Central PMCID: PMC4032712.2: Guo M, Lu XW, Ran XY, Hu RH. [Molecular transport mechanism of pefloxacin mesylate binding with transferrin]. Yao Xue Xue Bao. 2012 Nov;47(11):1503-10. Chinese. PubMed PMID: 23387084.3: Liu Y, Huang Y, Liu J, Wang W, Liu G, Zhao R. Superparamagnetic surface molecularly imprinted nanoparticles for water-soluble pefloxacin mesylate prepared via surface initiated atom transfer radical polymerization and its application in egg sample analysis. J Chromatogr A. 2012 Jul 13;1246:15-21. doi: 10.1016/j.chroma.2012.01.045. Epub 2012 Jan 25. PubMed PMID: 22321951.4: Liu R, Li N, Liu N, Zhou X, Dong ZM, Wen XJ, Liu LC. Effects of systemic ornidazole, systemic and local compound ornidazole and pefloxacin mesylate on experimental periodontitis in rats. Med Sci Monit. 2012 Mar;18(3):BR95-102. PubMed PMID: 22367122; PubMed Central PMCID: PMC3560749.5: Xie Y, Song Y, Zhang Y, Zhao B. Near-infrared spectroscopy quantitative determination of pefloxacin mesylate concentration in pharmaceuticals by using partial least squares and principal component regression multivariate calibration. Spectrochim Acta A Mol Biomol Spectrosc. 2010 May;75(5):1535-9. doi: 10.1016/j.saa.2010.02.012. Epub 2010 Feb 21. PubMed PMID: 20299275.6: Deng B, Li L, Shi A, Kang Y. Pharmacokinetics of pefloxacin mesylate in human urine using capillary electrophoresis electrochemiluminescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 15;877(24):2585-8. doi: 10.1016/j.jchromb.2009.06.021. Epub 2009 Jun 21. PubMed PMID: 19576860.7: Basavaiah K, Prameela HC, Somashekar BC. Spectrophotometric determination of pefloxacin mesylate in pharmaceuticals. Acta Pharm. 2007 Jun;57(2):221-30. PubMed PMID: 17507318.8: Fan JC, Chen X, Wang Y, Fan CP, Shang ZC. Binding interactions of pefloxacin mesylate with bovine lactoferrin and human serum albumin. J Zhejiang Univ Sci B. 2006 Jun;7(6):452-8. PubMed PMID: 16691639; PubMed Central PMCID: PMC1473993.9: Sultana Y, Aqil M, Ali A. Ion-activated, Gelrite-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv. 2006 May-Jun;13(3):215-9. PubMed PMID: 16556574.10: Sultana Y, Aqil M, Ali A. Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation. Acta Pharm. 2005 Sep;55(3):305-14. PubMed PMID: 16375841.11: Bharath S, Hiremath SR. Ocular delivery systems of pefloxacin mesylate. Pharmazie. 1999 Jan;54(1):55-8. PubMed PMID: 9987797.12: Isaacs RD, Ellis-Pegler RB. Successful treatment of Morganella morganii meningitis with pefloxacin mesylate. J Antimicrob Chemother. 1987 Nov;20(5):769-70. PubMed PMID: 3480886.13: Montay G, Goueffon Y, Roquet F. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother. 1984 Apr;25(4):463-72. PubMed PMID: 6587830; PubMed Central PMCID: PMC185553.14: Sultana Y, Aqil M, Ali A, Zafar S. Evaluation of carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol. 2006;11(3):313-9. PubMed PMID: 16895842.15: Chao JB, Tong HB, Liu DS, Huang SP. Preparation and characterization of inclusion complexes of pefloxacin mesylate with three kinds of cyclodextrins. Spectrochim Acta A Mol Biomol Spectrosc. 2006 May 1;64(1):166-70. Epub 2005 Aug 10. PubMed PMID: 16098803.16: Sultana Y, Jha MC, Ali A, Aqil M. A three-way comparative study on the efficacy of twin sol to gel systems and marketed eye drops of pefloxacin mesylate. J Ocul Pharmacol Ther. 2004 Aug;20(4):363-71. PubMed PMID: 15321031.17: Pozdniakova VP, Nestetrova LIa, Smirnova LB, Iakovlev VP, Blatun LA, Koshil/’ OI, Fedorov SM, Bakalova LA, Strachunskiĭ LS, Kurmanova KB. [Pefloxacin mesylate–clinical effectiveness in various forms of infectious-inflammatory diseases]. Antibiot Khimioter. 1997;42(7):20-3. Russian. PubMed PMID: 9334143.18: Rose TF, Ellis-Pegler R, Collins J, Small M. Oral pefloxacin mesylate in the treatment of continuous ambulatory peritoneal dialysis associated peritonitis: an open non-comparative study. J Antimicrob Chemother. 1990 May;25(5):853-9. PubMed PMID: 2373667.